Guardant Health (NASDAQ:GH) Upgraded by Mizuho to Strong-Buy Rating

Mizuho upgraded shares of Guardant Health (NASDAQ:GH) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports.

A number of other equities analysts have also recently commented on the company. Raymond James reaffirmed an “outperform” rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Stifel Nicolaus lifted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Barclays dropped their price target on Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Thursday. Stephens reaffirmed an “overweight” rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Finally, The Goldman Sachs Group boosted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $49.00.

Guardant Health Stock Down 0.3 %

Shares of NASDAQ:GH traded down $0.12 on Wednesday, hitting $41.03. 73,650 shares of the company traded hands, compared to its average volume of 2,127,313. The company has a market cap of $5.06 billion, a PE ratio of -11.59 and a beta of 1.45. The stock has a 50 day simple moving average of $43.64 and a 200-day simple moving average of $35.54. Guardant Health has a 52 week low of $15.81 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, sell-side analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of GH. R Squared Ltd purchased a new stake in shares of Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. acquired a new stake in Guardant Health during the fourth quarter worth $43,000. Kimelman & Baird LLC purchased a new stake in Guardant Health in the fourth quarter valued at $58,000. NewEdge Advisors LLC lifted its stake in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health during the 4th quarter worth $61,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.